Company
RAPT Therapeutics
Relentlessly focused on advancing treatments for patients with inflammatory and immunologic diseases
Also known as RAPT Therapeutics, Inc.
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Legal name
- RAPT Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases. Our cutting-edge science is fully focused on developing therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammatory and immunologic diseases, and improve and empower countless lives.
Funding snapshot
- Total raised
- $317MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $150M2024-12-27
Funding rounds
- Round, 2024
- $150M2024-12-27, SEC form D sold, 20 investors
- Round, 2022
- $50M2022-05-27, SEC form D sold, 1 investor
- Round, 2018
- $37.1M2018-12-18, SEC form D sold, 24 investors
- Round, 2017
- $29.9M2017-12-15, SEC form D sold, 10 investors
- Round, 2016
- $50M2016-04-21, SEC form D sold, 9 investors
About the company
- Status notes
- GSK has acquired RAPT Therapeutics
Products
- Other
- Ozureprubart
Exit
- Acquisition
- 2026-01-20
Loading relationship preview